Thermo Fisher Scientific (NYSE:TMO) Raised to “Strong-Buy” at Wolfe Research

Posted by George Bondi on Jun 3rd, 2026

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) was upgraded by investment analysts at Wolfe Research to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

A number of other research firms have also recently issued reports on TMO. Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Morgan Stanley reaffirmed an “overweight” rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Barclays dropped their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Finally, Royal Bank Of Canada set a $490.00 price objective on Thermo Fisher Scientific and gave the company a “sector perform” rating in a research note on Thursday, May 14th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $613.67.

Read Our Latest Analysis on TMO

Thermo Fisher Scientific Trading Down 2.7%

TMO stock opened at $480.62 on Monday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The company has a fifty day moving average price of $480.40 and a two-hundred day moving average price of $533.68. Thermo Fisher Scientific has a one year low of $385.46 and a one year high of $643.99. The stock has a market cap of $178.61 billion, a price-to-earnings ratio of 26.42, a price-to-earnings-growth ratio of 2.19 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same period last year, the firm posted $5.15 earnings per share. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities analysts anticipate that Thermo Fisher Scientific will post 24.86 EPS for the current year.

Insider Transactions at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of large investors have recently modified their holdings of TMO. High Note Wealth LLC raised its stake in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after acquiring an additional 29 shares in the last quarter. Swiss RE Ltd. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $28,000. Beacon Financial Strategies CORP purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at $29,000. Olistico Wealth LLC bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $29,000. Finally, Legacy Wealth Managment LLC ID increased its stake in shares of Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after acquiring an additional 22 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

About Thermo Fisher Scientific

(Get Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.